RxDoctor Payments Data

Mirian Boci, MD

Urology · Overland Park, KSNPI 1922272517

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,697 of the $6,874 with a category attached, or 82.9%. 45 manufacturers reported payments, led by Teleflex LLC at 26.6% of the total. 2025 is the largest year on record at $2,399, 2.2 times the $1,070 reported in 2019.

$6,874in general payments, 2019–2025

Across 240 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • AbbVie$703
  • Antares Pharma, Inc.$450
  • Procept Biorobotics Corporation$407
  • Johnson & Johnson$344
  • Astellas Pharma US Inc$267
  • plus $3K from 39 others

What the payments were for

  • Travel & lodging$90913%
  • Food & beverage$5,69783%
  • Education$2694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,874 in reported general payments places this provider in the 75th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$344,379
Medicare patients
615
Services billed
7,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron190$124,920
MyrbetriqMirabegron105$91,673
Potassium Citrate ErPotassium Citrate105$10,852
Tamsulosin Hcl607$9,349
Solifenacin Succinate227$7,554
Finasteride359$3,421
Desmopressin Acetate27$3,124
Tolterodine Tartrate ErTolterodine Tartrate11$2,689
Testosterone30$2,405
Silodosin37$2,259
Cephalexin87$1,860
Methenamine Hippurate35$1,641
Estradiol17$1,062
Trimethoprim19$920
Dutasteride26$879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$138$124,920190 claims
Astellas Pharma US IncMyrbetriq$267$91,673105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 urology providers in Kansas.

Other urology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →